Novavax Inc., a Gaithersburg biotech company, is pleased with its progress as it shows another quarterly loss.
Novavax had a loss of $44.5 million in its second quarter, a lesser loss than the same quarter a year before of $79.4 million. Revenue increased 169 percent from $2.5 million in the same period in 2016 to $6.7 million, mainly because of a grant related to a clinical trial for its respiratory syncytial virus F-protein nanoparticle vaccine candidate.
Among the accomplishments the company noted in the second quarter and afterward are its flu vaccine candidate performing well in preclinical studies, and positive results in trials of its RSV F vaccine candidate. The vaccine candidate is also part of a global trial for infants, via maternal immunization, which now has 80 enrollment sites in 11 countries.